Citations
Citations
Citations
Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
To investigate the clinical characteristics that significantly contribute to a decreased bone mineral density (BMD), the BMD changes and clinical characteristics of men who experienced a stroke between the ages of 50 years and 65 years were studied between 3 months and 4 months after the stroke.
Subjects had a brain hemorrhage or a cerebral infarction. Only men aged 50 years to 65 years were included to eliminate postmenopausal osteoporosis and to eliminate the influence of senile osteoporosis. All subjects underwent a BMD test between 3 months and 4 months after their strokes. Also, patients with a medication history that might have caused a secondary osteoporosis before a stroke were excluded.
The BMD for the lumbar spine and hemiplegic side of the femoral neck correlated significantly with the results of the manual muscle test (MMT) of the hemiplegic lower extremity and the Modified Barthel Index (MBI) score. This result suggests that the immobility from the decreased muscle strength and the weakened daily functionality might have reduced the BMD. According to a multiple linear regression analysis, the MBI score is significantly correlated with the lumbar BMD. The BMD of the hemiplegic femoral neck is significantly correlated with the MMT and the MBI score.
This study showed that BMD monitoring should be considered in male stroke patients, especially for patients with a high dependency in daily functions and a decreased muscle strength in the hemiplegic lower extremity.
Citations
Method: The experimented rats were total 50 Sprague- Dawley female rats. They were divided randomly 5 groups. The treatment was initiated on the first day after surgery and continued for a period of 4 weeks. Bone measurements were performed in the distal femoral metaphysis and 5th lumbar vertebrae with dual energy x-ray absorptiometry at the time of 2nd week and 4th week after drug injection in all groups.
Results: The cancellous bone density in the ovariectomized rats treated with high dose of the salmon calcitonin microspheres was significantly higher than that of the free salmon calcitonin-treated ovariectomized rats, but less than that of the sham-operated control rats.
Conclusion: This study shows that the salmon calcitonin microspheres were evaluated for protection against the cancellous bone loss in the ovariectomized rats. The bone protective effect of the salmon calcitonin microspheres was greater than that of the free salmon calcitonin. (J Korean Acad Rehab Med 2003; 27: 121-125)
Objective: This study was designed to evaluate the effect of growth hormone on bone mineral density of corticosteoid-induced osteoporosis in male rat.
Method: Twenty Sprague-Dwaley male rats was studied, divided into four group, each group has 5 rats. The group 1 was treated with saline. The group 2 was treated with corticosteroid (Methylprednisolone 10 mg/kg). The group 3 was treated with corticosteroid and growth hormone (recombinant human growth hormone 0.5 IU/kg). The group 4 was treated with growth hormone after corticosteroid treatment. The treatment duration was 6 weeks for each group. After six weeks of hormone administration, the animals were sacrificed, the bilateral femur were removed and tested for bone mineral density using dual energy X-ray absorptiometry and examined histomorphometrically.
Results: Administration of growth hormone after corticosteroid therapy, the growth hormone could reverse the decrease in body weight and bone mineral density induced by corticosteroid therapy (p＜0.05).
Conclusion: When growth hormone is administrated after corticosteroid therapy, the growth hormone can protect the osteoporosis in male rats induced by a high dose of corticosteroid.
First
Prev
